logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

New rituximab biosimilar demonstrates pharmacokinetic equivalence to reference product in advanced, treatment-naive DLBCL

Comparable rates of response at cycle 6.